BioSpace News Archive

The NDA was based on positive Phase III data that shows the once-a-month treatment is as effective as the daily standard of care.

An article published in Experimental Biology and Medicine details abnormalities in bone pathology that occur in systemic autoimmune disease.

BioArctic AB to publish the company’s Interim Report for the period January – March 2019 on Thursday, May 9, 2019 at 08:00 a.m. CET.

Polarean Imaging plc announces the appointment of Charles Osborne, Jr as Chief Financial Officer with immediate effect.

Healthcare Investor Conference in Toronto on April 30 & May 1

Akelos Inc., a biotechnology company currently developing and commercializing a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain, adds Dr. Charles Berde to its Scientific Advisory Board.

The U.S. Department of Health and Human Services Office of the Chief Technology Officer and the American Society of Nephrology have selected 15 winning teams for Phase 1 of the KidneyX Redesign Dialysis prize competition.

MorphoSys AG and I-Mab Biopharma announced that the first patient has been dosed in a phase 3 randomized and multi-center clinical study in Taiwan to evaluate MorphoSys’s investigational human CD38 antibody MOR202/TJ202 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

Motif Bio plc announced the appointment of Andrew Powell, J.D. as Non-executive Director, effective immediately.

Motif Bio plc announced that its notice of its Annual General Meeting have been posted to shareholders and will shortly be available for download from the Company’s website at www.motifbio.com.